Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Hollow Fiber Assay

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2786-2

Definition

The hollow fiber assay (HFA) is a fast in vivo assay to determine the cytotoxic effect of drugs, as well as their pharmacodynamic (Pharmacodynamics) effects on human tumor cell lines grown in hollow fibers that are implanted subcutaneously or intraperitoneally in mice or rats.

Characteristics

Various in vivo models exist to assess the efficacy of potential anticancer agents, including subcutaneously implanted xenografts, orthotopic models, and the HFA. The HFA has been optimized at the National Cancer Institute (NCI) and is a unique in vivo model for drug discovery. It permits the simultaneous evaluation of the efficacy of anticancer agents against multiple tumor cell lines in two physiological compartments of one animal. In this assay, semipermeable biocompatible fibers are used, which can be filled with cancer cells. These cancer cells can be derived from different tissue origins and can have different cellular characteristics. The fibers are made of polyvinylidene...

Keywords

National Cancer Institute Tumor Cell Line Xenograft Model Hollow Fiber Relative Tumor Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Decker S, Hollingshead M, Bonomi CA et al (2004) The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 40:821–826CrossRefPubMedGoogle Scholar
  2. Hollingshead MG, Alley MC, Camalier RF et al (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131–141CrossRefPubMedGoogle Scholar
  3. Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11:971–981PubMedGoogle Scholar
  4. Suggitt M, Cooper PA, Shnyder SD et al (2006) The hollow fibre model – facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. Int J Oncol 29:1493–1499PubMedGoogle Scholar
  5. Temmink OH, Prins HJ, van Gelderop E et al (2007) The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer 96:61–66CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Medical OncologyVU University Medical CenterAmsterdamThe Netherlands